241 related articles for article (PubMed ID: 36872052)
21. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
Ou SI; Hong JL; Christopoulos P; Lin HM; Vincent S; Churchill EN; Soeda J; Kazdal D; Stenzinger A; Thomas M
J Thorac Oncol; 2023 Jun; 18(6):744-754. PubMed ID: 36738930
[TBL] [Abstract][Full Text] [Related]
22. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Piotrowska Z; Tan DS; Smit EF; Spira AI; Soo RA; Nguyen D; Lee VH; Yang JC; Velcheti V; Wrangle JM; Socinski MA; Koczywas M; Janik JE; Jones J; Yu HA
J Clin Oncol; 2023 Sep; 41(26):4218-4225. PubMed ID: 37384848
[TBL] [Abstract][Full Text] [Related]
23. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
Zhang W; Dong X
J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
[TBL] [Abstract][Full Text] [Related]
24. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Pan B; Liang J; Shi H; Rao K; Guo W; Zhan C
Thorac Cancer; 2023 Nov; 14(33):3247-3258. PubMed ID: 37795778
[TBL] [Abstract][Full Text] [Related]
25. Real-World Clinical Outcomes for Patients with
Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
[TBL] [Abstract][Full Text] [Related]
26. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
[TBL] [Abstract][Full Text] [Related]
27. Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Christopoulos P; Prawitz T; Hong JL; Lin HM; Hernandez L; Jin S; Tan M; Proskorovsky I; Lin J; Zhang P; Patel JD; Ou SI; Thomas M; Stenzinger A
Lung Cancer; 2023 May; 179():107191. PubMed ID: 37058788
[TBL] [Abstract][Full Text] [Related]
28. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
Shaffer W; Kobayashi IS; Sentana-Lledo D; Sundararaman S; Lee MD; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
Lung Cancer; 2023 Jul; 181():107250. PubMed ID: 37196448
[TBL] [Abstract][Full Text] [Related]
29. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
Brazel D; Kroening G; Nagasaka M
BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589
[TBL] [Abstract][Full Text] [Related]
30. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
31. EGFR exon 20 insertion mutations in non-small cell lung cancer.
Wang F; Li C; Wu Q; Lu H
Transl Cancer Res; 2020 Apr; 9(4):2982-2991. PubMed ID: 35117654
[TBL] [Abstract][Full Text] [Related]
32. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients.
Xu Y; Jia L; Zhang L; Wang H; Jiang L; Feng X; Wei R; Yao Q; Ren M; Xue T; Li Y; Zhu X; Zhou X; Bai Q
Transl Lung Cancer Res; 2024 May; 13(5):986-997. PubMed ID: 38854943
[TBL] [Abstract][Full Text] [Related]
34. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with
Xu CW; Wang WX; Wang D; Wang QM; Pu XX; Zhu YC; Huang JH; Yu ZY; Cui ZL; Chen XH; Li JL; Fang Y; Wang H; Zhuang W; Lan SJ; Cai X; Zhang YB; Gao WB; Wang LP; She KL; Rao CZ; Zhou YF; Fang MY; Miao LY; Lei L; Lv TF; Song Y
Transl Lung Cancer Res; 2020 Oct; 9(5):1853-1861. PubMed ID: 33209607
[TBL] [Abstract][Full Text] [Related]
35. Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and
Luo Q; Chen L; Li Z; Cheng L; Zhang S; Zong Y; Li Q; Suda K; Santarpia M; Dalia S; Meng R
Transl Lung Cancer Res; 2023 Nov; 12(11):2330-2341. PubMed ID: 38090524
[TBL] [Abstract][Full Text] [Related]
36. The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives.
Dorta-Suárez M; de Miguel M; Amor-Carro O; Calderón JM; González-Ortega M; Rodríguez-Abreu D
Cancer Treat Rev; 2024 Mar; 124():102671. PubMed ID: 38281403
[TBL] [Abstract][Full Text] [Related]
37. EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Shah MP; Aredo JV; Padda SK; Ramchandran KJ; Wakelee HA; Das MS; Neal JW
Clin Lung Cancer; 2022 Mar; 23(2):e148-e153. PubMed ID: 34391686
[TBL] [Abstract][Full Text] [Related]
38. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
[TBL] [Abstract][Full Text] [Related]
39. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
Yang X; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
[TBL] [Abstract][Full Text] [Related]
40. Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
Jatkoe T; Wang S; Odegaard JI; Velasco Roth AM; Osgood D; Martinez G; Lucas P; Curtin JC; Karkera J
J Mol Diagn; 2022 Nov; 24(11):1181-1188. PubMed ID: 35963523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
